Department of Hematology and Oncology, University Clinic of Freiburg, Freiburg, Germany.
J Cell Physiol. 2010 Nov;225(3):792-800. doi: 10.1002/jcp.22284.
CCL18 and CXCL12 are homeostatic chemokines with high constitutive concentrations in serum. Elevated levels of CCL18 have been described in various diseases including childhood acute lymphocytic leukemia (ALL) but its functions remain poorly characterized. Its receptor has not been identified, but functional cellular responses like lymphocyte chemotaxis have been described. CXCL12 is a pivotal chemokine for hematopoiesis and B cell homing processes. We demonstrate that CCL18 interferes with CXCL12-mediated pre-B ALL cell activation. CXCL12-induced calcium mobilization, chemotaxis, pseudo-emperipolesis and cellular proliferation could be significantly reduced by CCL18 in pre-B ALL cell lines. The results could be observed in primary cells from patients suffering from pre-B ALL, but not in cells from patients suffering from common ALL. Direct effects of CCL18 on the receptor for CXCL12, CXCR4, could be excluded. Moreover, we found that CCL18 modulations of CXCL12-induced responses are mediated through the chemokine-like receptor GPR30. CCL18 bound to GPR30 expressing cells, and antibodies against GPR30 abolished this binding as well as CCL18-mediated functional effects. We also observed that, CCL18 interferes with the activation of GPR30 by previously identified ligands (17β-estradiol and chemical agonists). We therefore suggest that CCL18 is an important modulator of CXCR4-dependent responses in pre-B ALL cells via interactions with GPR30.
CCL18 和 CXCL12 是具有高固有浓度的稳态趋化因子,在血清中。CCL18 的水平在各种疾病中升高,包括儿童急性淋巴细胞白血病(ALL),但其功能仍未得到充分描述。其受体尚未被鉴定,但已描述了淋巴细胞趋化等功能性细胞反应。CXCL12 是造血和 B 细胞归巢过程的关键趋化因子。我们证明 CCL18 干扰 CXCL12 介导的前 B ALL 细胞激活。CCL18 可显著减少前 B ALL 细胞系中 CXCL12 诱导的钙动员、趋化、假足形成和细胞增殖。这些结果在前 B ALL 患者的原代细胞中可以观察到,但在患有普通 ALL 的细胞中则不能观察到。可以排除 CCL18 对 CXCL12 受体 CXCR4 的直接作用。此外,我们发现 CCL18 对 CXCL12 诱导的反应的调节是通过趋化因子样受体 GPR30 介导的。CCL18 结合表达 GPR30 的细胞,针对 GPR30 的抗体可消除这种结合以及 CCL18 介导的功能效应。我们还观察到,CCL18 干扰先前鉴定的配体(17β-雌二醇和化学激动剂)对 GPR30 的激活。因此,我们认为 CCL18 通过与 GPR30 相互作用,是前 B ALL 细胞中 CXCR4 依赖性反应的重要调节剂。